Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Buy Us a Coffee
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2024-45640
Vulnerability Information
Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
IBM Security QRadar EDR information disclosure
Source: NVD (National Vulnerability Database)
Vulnerability Description
IBM Security ReaQta 3.12 returns sensitive information in an HTTP response that could be used in further attacks against the system.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N
Source: NVD (National Vulnerability Database)
Vulnerability Type
将系统数据暴露到未授权控制的范围
Source: NVD (National Vulnerability Database)
Vulnerability Title
IBM Security ReaQta 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
IBM Security ReaQta是美国国际商业机器（IBM）公司的一个 AI 自主检测和响应平台。 IBM Security ReaQta 3.12版本存在安全漏洞，该漏洞源于HTTP响应中返回敏感信息，这些信息可能被用于对系统进行进一步攻击。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
IBMSecurity QRadar EDR 3.12 cpe:2.3:a:ibm:security_qradar_edr:3.12:*:*:*:*:*:*:*
II. Public POCs for CVE-2024-45640
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2024-45640
Please Login to view more intelligence information
IV. Related Vulnerabilities
Same product: Security QRadar EDR
Same vendor: IBM
Same weakness: CWE-497
V. Comments for CVE-2024-45640

No comments yet

Leave a comment